I watched this webinar on siRNA by Louis Baskin.
Post# of 5066
Not sure here, but I believe Regen has a lead in the area not really covered in the webinar. This is about LONG-TERM knock-down of the gene. On-target plus product and reagents are (i think) short duration silencing. The product not covered as much is their Accell, where they have delivery issues and lower garentee. I believe information posted by the company on DcellVax has shown effective LONG-TERM silencing (and in human subject). Also an issue is delivery and chemical reagent used in the operational effectiveness in the double strand siRNA. Now, if you look again at PRs released, you will find one that mentions reagents specifically and the company's excitement to patent these reagents discovered.
well, there is much more to say on all that, but just wanted to share what i have gleaned thus far and encourage you all to check out the webinar. (I believe it is replaying now)